

Docket Number: 018743-0276324

PATENT APPLICATION

Client Reference: (CHOP-0088)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

KATHERINE A HIGH, et al.

Group Art Unit: 1643

Application No.: 09/589,589

Examiner: Whiteman, Brian A.

Filed: June 8, 2000

Confirmation No.: 1864

For: METHODS FOR PREVENTING FORMATION OF INHIBITORY ANTIBODIES IN
SETTING OF GENE THERAPY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Applicants respectfully request the Examiner return an initialed copy of the enclosed Form PTO-1449 to Applicants with the next Office communication to indicate that the reference(s) has been considered, per MPEP § 609.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Please charge Deposit Account 033975 in the amount of \$180.00 in payment of the fee under 37 CFR 1.17(i)(p). Please credit or debit Deposit Account 033975 as needed to ensure consideration of the disclosed information.

I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR 1.97(e)(2).

Respectfully Submitted,

PILLSBURY WINTHROP SHAW PITTMAN LLP



Robert M. Bedgood

Registration Number 43488

Customer Number: 27500

Date: June 11, 2007
Telephone: (619) 234-5000
Facsimile: (858) 509-4010
12255 El Camino Real
Suite 300
San Diego, CA 92130

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

018743-0276324

CHOP-0088

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Christophe Dauga, et al.

Appln. No.: 09/589,589

Filing Date: June 8, 2000

Date: 06/11/07

Page

1

of

1

Examiner: Saadat, C.

Group Art Unit: 1643

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR						
	BR						
	CR						
	DR						
	ER						
	FR						
	GR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
							Enclosed	No	Enclose	No
	HR									
	IR									
	JR									
	KR									
	LR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

MR	Herzog, R.W., et al., Long-Term Correction of Canine Hemophilia B by Gene Transfer of Blood Coagulation Factor IX Mediated by Adeno-Associated Viral Vector, Nature Medicine, 5(1):56-63 (1999)			
NR	Snyder, R. O., Correction of Hemophilia B in Canine and Murine Models Using Recombinant Adeno-Associated Viral Vectors, Nature Medicine, 5(1):64-70 (1999)			
OR				
PR				
QR				
RR				

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.